Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

SGH will process cord blood to develop and produce allogeneic chimeric antigen receptor (CAR) T-cells designed for cancer treatment.

Hyderabad (Telangana) [India], February 25 (ANI): Biological E Limited (BE) on Tuesday announced a strategic partnership with Bavarian Nordic A/S (OMX: BAVA) to expand access to Bavarian Nordic's ...

Levi & Korsinsky, LLP notifies investors in GSK plc ("GSK" or the "Company") of a class action securities lawsuit. CLASS ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...